Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BRIM 3: A Randomized, Open-Label, Controlled, Multicenter, Phase III Study in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving Vemurafenib (RO5185426) or Dacarbazine
Brief Summary: This randomized, open-label study evaluated the efficacy, safety and tolerability of vemurafenib (RO5185426) as compared to dacarbazine in previously untreated patients with metastatic melanoma. Patients were randomized to receive either vemurafenib 960 mg orally twice daily or dacarbazine 1000 mg/m2 intravenously every 3 weeks. Study treatment was continued until disease progression or unacceptable toxicity occurred. The data and safety monitoring board recommended that patients in the dacarbazine group be allowed to cross over to receive vemurafenib, and the protocol was amended accordingly on January 14, 2011, as both overall survival and progression-free survival endpoints had met the prespecified criteria for statistical significance in favor of vemurafenib.


Options:
A: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
B: Arm Label: Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Placebo for Nivolumab, Biological: Placebo for Ipilimumab | Arm Label: Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Biological: Placebo for Nivolumab | Arm Label: Arm C: Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab, Biological: Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab, Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab, Arm C: Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Placebo for Nivolumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab, Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab, Arm C: Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Placebo for Ipilimumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab
C: Arm Label: GSK2118436; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Arm Label: Dacarbazine (DTIC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine (DTIC) | Arm Label: Crossover; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Intervention Type: DRUG; Name: GSK2118436; Assigned to Arm(s): Crossover, GSK2118436 | Intervention Type: DRUG; Name: Dacarbazine (DTIC); Assigned to Arm(s): Dacarbazine (DTIC)
D: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Pembrolizumab, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab, Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A